ANAVEX LIFE SCIENCES CORP. AVXL

Rank #1689 · Nasdaq · $0.1B market cap

Audited by GRANT THORNTON LLP, no going-concern flag in the latest filing.

Score

44.3

P/E

-2.3

P/B

0.77

ROE

-33.3%

Op. Margin

–%

Debt Ratio

11%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆

Average

P/E -2.3x, P/B 0.77x. Ranks in the top 52% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -33.3%. Ranks in the top 85% of the universe.

Safety ★★★★☆

Excellent

Debt ratio 11%. Ranks in the top 10% of the universe. Under 100% is generally considered a safe level.

Growth –

No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2011	–	$-0.0B	$-0.0B	$0.0B	–	12849
2012	–	$-0.0B	$-0.0B	$0.0B	–	5255
2013	–	$-0.0B	$-0.0B	$0.0B	–	11280
2014	–	$-0.0B	$-0.0B	$-0.0B	–	-99
2015	–	–	$-0.0B	$-0.0B	–	-291
2016	–	–	$-0.0B	$-0.0B	–	-108
2017	–	–	$-0.0B	$0.0B	–	1656
2018	–	–	$-0.0B	$0.0B	–	117
2019	–	–	$-0.0B	$0.0B	–	1
2020	–	–	$-0.0B	$0.0B	–	23
2021	–	–	$-0.0B	$0.0B	–	36
2022	–	$-0.0B	$-0.0B	$0.0B	–	53
2023	–	$-0.0B	$-0.0B	$0.0B	–	38
2024	–	$-0.1B	$-0.0B	$0.1B	–	9
2025	–	$-0.1B	$-0.0B	$0.1B	–	11